Cargando…

Need to focus on inhibitory activity of benzimidazole analogues against indolamine 2,3-dioxygenase-1 (IDO-1)

Detalles Bibliográficos
Autores principales:	Sharma, Akshansh, Tonk, Rajiv, Shekhar, Ravi, Dohare, Sushil, Kumar, Deepak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441679/ https://www.ncbi.nlm.nih.gov/pubmed/36110557 http://dx.doi.org/10.17179/excli2022-4988

Ejemplares similares

Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
por: Monjazeb, Arta M, et al.
Publicado: (2013)

Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1) Expression via a Dual Mechanism in Human Intestinal Epithelial Cells
por: Martin-Gallausiaux, Camille, et al.
Publicado: (2018)

Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain
por: Herrera-Rios, Dayana, et al.
Publicado: (2020)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Blocking indolamine 2,3 dioxygenase mediated rebound immune suppression improves systemic anti-tumor effects of radio-immunotherapy
por: Monjazeb, Arta M, et al.
Publicado: (2015)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Limited Effect of Indolamine 2,3-Dioxygenase Expression and Enzymatic Activity on Lupus-Like Disease in B6.Nba2 Mice
por: Davison, Laura M., et al.
Publicado: (2019)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
por: Tang, Kai, et al.
Publicado: (2021)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma
por: Chakwizira, Arthur, et al.
Publicado: (2018)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
por: Röhrig, Ute F., et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
por: Pallotta, Maria Teresa, et al.
Publicado: (2021)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
por: Bonanno, Giuseppina, et al.
Publicado: (2012)

Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
por: Driessens, Gregory, et al.
Publicado: (2014)

Indoleamine 2,3-Dioxygenase 1 (Ido1) Is Involved in the Control of Mouse Caput Epididymis Immune Environment
por: Jrad-Lamine, Aicha, et al.
Publicado: (2013)

Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production
por: Bellucci, Michele, et al.
Publicado: (2021)

Combined Inhibition of Indolamine-2,3-Dioxygenase 1 and C-X-C Chemokine Receptor Type 2 Exerts Antitumor Effects in a Preclinical Model of Cervical Cancer
por: Lizcano-Meneses, Solangy, et al.
Publicado: (2023)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
por: Lee, Dong-Ho, et al.
Publicado: (2017)

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
por: Zhao, Hongchuan, et al.
Publicado: (2019)

Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells
por: Sadok, Ilona, et al.
Publicado: (2021)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
por: Alves de Souza, Thiara Manuele, et al.
Publicado: (2022)

Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma
por: Jiang, Guan-Min, et al.
Publicado: (2015)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
por: Huang, Guanyou, et al.
Publicado: (2012)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
por: Wongpraparut, Nattawut, et al.
Publicado: (2021)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
por: Folgiero, Valentina, et al.
Publicado: (2013)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study
por: Scagnolari, Carolina, et al.
Publicado: (2016)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
por: Yang, Pengbo, et al.
Publicado: (2023)

Analysis of indoleamine 2,3-dioxygenase 1 (IDO1) expression of cultured cord blood adherent mononuclear cells as an indicator of atopic risk
por: Zhu, Yifei, et al.
Publicado: (2014)

Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
por: Iachininoto, Maria Grazia, et al.
Publicado: (2013)

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
por: Xu, Xi, et al.
Publicado: (2019)

Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis
por: Wirthgen, Elisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4h03vkvr4bdlqqj7mdt5tlilqj